NY-IL-MAKIAGE/VOYAGE81
12.8.2021 14:02:08 CEST | Business Wire | Press release
IL MAKIAGE, the fastest growing beauty company in the U.S., today announces the acquisition of Voyage81, a deep-tech AI-based computational imaging startup. IL MAKIAGE’s acquisition of Voyage81 will enable the company to use Voyage81’s patented hyperspectral imaging systems to further enhance the company’s machine learning capabilities and aligns with IL MAKIAGE's commitment to continue innovating and revolutionizing the beauty and wellness industries at-large. It also sets the stage for the company’s planned new brand launches within the beauty and wellness domains. The acquisition is the company’s second technology acquisition in the last 24 months.
Voyage81 is the first and only company in the world to develop patented software that brings hyperspectral imaging capabilities to smartphones. Voyage81’s software extracts over 30 channels of hyperspectral information from RGB images taken with existing smartphone cameras. In addition to its vision software, Voyage81 is currently developing a hardware-based solution, in tandem with some of the largest global smartphone manufacturers, that builds on the company’s hyperspectral software to significantly enhance photos taken in low-light conditions.
IL MAKIAGE CEO Oran Holtzman says, “For the past two years, we have been searching for computational imaging solutions that can work in beauty and wellness to further advance our existing AI capabilities. I have met dozens of computer vision startups but could not find a technology that can fit our industry and was strong enough to fulfill our goals. Bringing on Voyage81’s patented technology and exceptional team to our tech and data science departments is a huge win for our company's future, our users, and the industry at-large."
The implications of Voyage81's technology for the beauty and wellness industries are endless. Voyage81’s software is capable of mapping and analyzing skin and hair features, detecting facial blood flows, and creating melanin and hemoglobin maps from a simple smartphone camera photo. The technology, combined with IL MAKIAGE’s current AI algorithms, will leverage users' personal smartphone cameras to provide unparalleled online matching capabilities to users of IL MAKIAGE and its upcoming homegrown digital beauty and wellness brands.
Voyage81 was founded in 2019 by CEO Niv Price, former head of R&D at Unit 81, the most elite technological unit in the Israeli Defense Forces (the unit’s alumnus are known to have founded some of the most successful start-ups in Israel), Dr. Boaz Arad (CTO), a Ph.D. in Computer Vision and a key opinion leader in the hyperspectral space, Dr. Rafi Gidron, an accomplished and well-known Israeli hi-tech serial entrepreneur (including Chromatis Networks, sold to Lucent), and Omer Shwartz (Software Lead), a Ph.D. in Cyber Security.
Voyage81’s computer vision capabilities and team (half of whom hold PhDs) will be integrated within IL MAKIAGE's data science capabilities and its matching algorithms to serve the company's tens of millions of users and customers. Voyage81 founders, Niv Price, Dr. Arad and Omer Shwartz, will take leadership roles in IL MAKIAGE. Price will serve as CTO, Dr. Arad will serve as Chief Vision Officer, while Shwartz will serve as VP of Information Security. All three will also continue to lead Voyage81 as CEO, CTO and Software Lead.
“When we met Oran, we were focused on our own rapid growth trajectory with no plans at all to sell," notes Price, Voyage81 co-founder and CEO. "In fact, we just finished round A funding and were already working with the largest smartphone manufacturers in the world. But after meeting Oran and learning about the company’s long-term vision, we realized that under the IL MAKIAGE platform, Voyage81 technology will serve and benefit hundreds of millions of consumers, fulfilling our founding goal.”
"The technological advancements for IL MAKIAGE are immense," said Holtzman. "The software-only hyperspectral expansion, which requires only a traditional image from any smartphone camera, will be immediately integrated into the company's consumer experience. The addition of these vision capabilities provides another dimension of information which will allow us to rapidly expand our capabilities in existing and future domains with lower amount of data needed for our machine learning models."
Voyage81 co-founder and CTO, Dr. Arad said, “Combining Voyage81’s physics-based algorithms with IL MAKIAGE’s existing data science team and utilizing the company’s one billion+ data points and unprecedented daily incoming data flow, will further boost our AI vision capabilities. Thus, I strongly believe that together we can conquer the next frontier in the beauty and wellness industries – creating a technological advantage that will be next to impossible to match.”
Voyage81’s technology was developed based on the doctoral research of Dr. Arad who was examining by how much the estimation of hyperspectral information from RGB data would be inferior to professional hyperspectral camera results. When he saw that the results were almost comparable, he thought he had introduced some errors into the comparison process, but after deep investigation he realized he was on to an exciting discovery that has the potential to reverberate throughout the world.
About IL MAKIAGE
Launched in the US in 2018 by brother-sister duo entrepreneurs, IL MAKIAGE is a New York based, tech-driven prestige DTC beauty company. IL MAKIAGE is defining and building the future of beauty by using proprietary technology to connect people with superior, painstakingly tested, beauty products. Following the company’s major success as the fastest-growing online beauty brand in the US, IL MAKIAGE continues to shift millions of customers from offline to online and it recently expanded to the UK, Canada, Germany and Australia. IL MAKIAGE is backed by L Catterton, the leading consumer-focused private equity company in the world. For more information, visit www.ilmakiage.com
.
About Voyage81
Founded in 2019, Voyage81 is a deep-tech AI-based computational imaging company that developed a patented software which recovers over 30 channels of hyperspectral information from any simple smartphone camera with no additional hardware, charting a path to revolutionize the beauty and wellness industries. Voyage81, led by alumni of the top elite Israeli intelligence units as well as computer vision PhDs, is also developing in partnership with some of the largest global smartphone manufacturers a hardware-based solution that builds on the company’s hyperspectral software to significantly enhance photos taken in low-light conditions. Voyage81 is backed by True Ventures, Next Gear Ventures, Maniv Mobility and iAngels. For more information, visit www.voyage81.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
